In a retrospective study GLP-1 agonists have been shown to be associated with lower rates of hepatic decompensations compared to other glycemic agents, although more prospective data is needed
Balancing The Microbiome Mold exposure can disturb the delicate balance of the gut microbiome, influencing overall health
Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Ryden L: Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
The trial, conducted across multiple international sites and involving 725 adults living with obesity or overweight but without type 2 diabetes, concluded in April 2026 after 76 weeks of treatment